

## Lipopolysaccharide Lowers Cholesteryl Ester Transfer Protein by Activating F4/80<sup>+</sup>Clec4f<sup>+</sup>Vsig4<sup>+</sup>Ly6C<sup>-</sup> Kupffer Cell Subsets

Sam J. L. van der Tuin, PhD;\* Zhuang Li, MSc;\* Jimmy F. P. Berbée, PhD; Inge Verkouter, MSc; Linda E. Ringnalda, MSc; Annette E. Neele, MSc; Jan B. van Klinken, PhD; Sander S. Rensen, PhD; Jingyuan Fu, PhD; Menno P. J. de Winther, PhD; Albert K. Groen, PhD; Patrick C. N. Rensen, PhD; Ko Willems van Dijk, PhD; Yanan Wang, PhD

**Background**—Lipopolysaccharide (LPS) decreases hepatic CETP (cholesteryl ester transfer protein) expression albeit that the underlying mechanism is disputed. We recently showed that plasma CETP is mainly derived from Kupffer cells (KCs). In this study, we investigated the role of KC subsets in the mechanism by which LPS reduces CETP expression.

**Methods and Results**—In CETP-transgenic mice, LPS markedly decreased hepatic *CETP* expression and plasma CETP concentration without affecting hepatic macrophage number. This was paralleled by decreased expression of the resting KC markers C-type lectin domain family 4, member f (*Clec4f*) and V-set and immunoglobulin domain containing 4 (*Vsig4*), while expression of the infiltrating monocyte marker lymphocyte antigen 6 complex locus C (*Ly6C*) was increased. Simultaneously, the ratio of plasma high-density lipoprotein-cholesterol over non-high-density lipoprotein-cholesterol transiently increased. After ablation hepatic macrophages via injection with liposomal clodronate, the reappearance of hepatic gene and protein expression of CETP coincided with *Clec4f* and *Vsig4*, but not *Ly6C*. Double-immunofluorescence staining showed that CETP co-localized with *Clec4f*<sup>+</sup> KCs and not *Ly6C*<sup>+</sup> monocytes. In humans, microarray gene-expression analysis of liver biopsies revealed that hepatic expression and plasma level of CETP both correlated with hepatic *VSIG4* expression. LPS administration decreased the plasma CETP concentration in humans. In vitro experiments showed that LPS reduced liver X receptor-mediated CETP expression.

**Conclusions**—Hepatic expression of CETP is exclusively confined to the resting KC subset (ie, F4/80<sup>+</sup>Clec4f<sup>+</sup>Vsig4<sup>+</sup>Ly6C<sup>-</sup>). LPS activated resting KCs, leading to reduction of *Clec4f* and *Vsig4* expression and reduction of hepatic CETP expression, consequently decreasing plasma CETP and raising high-density lipoprotein (HDL)-cholesterol. This sequence of events is consistent with the anti-inflammatory role of HDL in the response to LPS and may be relevant as a defense mechanism against bacterial infections. (*J Am Heart Assoc.* 2018;7:e008105. DOI: 10.1161/JAHA.117.008105.)

**Key Words:** inflammation • lipids and lipoprotein metabolism • liver • macrophage • marker

**K**upffer cells (KCs) are the resident tissue macrophages of the liver. KCs are characterized by specific surface proteins such as *Clec4f* (C-type lectin domain family 4, member f) and *Vsig4* (V-set and immunoglobulin domain containing 4).<sup>1–4</sup> These surface markers distinguish KCs from other hepatic macrophages, which may have lost or have yet

to acquire these KC markers. KCs play an important role in the response to various harmful agents such as intestine-derived bacterial lipopolysaccharide (LPS) in the portal blood. LPS, a constituent of Gram-negative bacteria, is a potent endotoxin that induces a strong cytokine-mediated inflammatory response in the host.<sup>5</sup> LPS activates KCs via the Toll-like

From the Division of Endocrinology, Department of Medicine (S.J.L.v.d.T., Z.L., J.F.P.B., I.V., L.E.R., P.C.N.R., K.W.v.D., Y.W.), Eindhoven Laboratory for Experimental Vascular Medicine (S.J.L.v.d.T., Z.L., J.F.P.B., P.C.N.R., K.W.v.D., Y.W.), and Department of Human Genetics (J.B.v.K., K.W.v.D.), Leiden University Medical Center, Leiden, The Netherlands; Amsterdam Diabetes Center, Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, The Netherlands (A.K.G.); Department of Pediatrics (J.F., A.K.G., Y.W.) and Department of Genetics, University Medical Center Groningen (J.F.), University of Groningen, The Netherlands; Department of Medical Biochemistry, Academic Medical Center, Amsterdam, The Netherlands (A.E.N., M.P.J.d.W.); Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands (S.S.R.); Institute for Cardiovascular Prevention (IPEK), Ludwig Maximilian's University, Munich, Germany (M.P.J.d.W.).

Accompanying Table S1 and Figures S1 through S4 are available at <http://jaha.ahajournals.org/content/7/6/e008105/DC1/embed/inline-supplementary-material-1.pdf>

\*Dr van der Tuin and Dr Li contributed equally to this work.

**Correspondence to:** Yanan Wang, PhD, Division of Endocrinology, Department of Medicine, Leiden University Medical Center, P.O. Box 9600, Leiden 2300 RC, The Netherlands. E-mail: [y.wang@lumc.nl](mailto:y.wang@lumc.nl)

Received November 28, 2017; accepted February 1, 2018.

© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

## Clinical Perspective

### What Is New?

- Our findings show that hepatic CETP (cholesteryl ester transfer protein) is exclusively expressed by a resting Kupffer cell subset (ie, F4/80<sup>+</sup>Ly6C<sup>-</sup>Clec4f<sup>+</sup>) but not by activated macrophages or monocytes in the liver.
- Lipopolysaccharide exposure reduces hepatic CETP expression by activation of resting Kupffer cells, consequently decreasing plasma CETP and raising high-density lipoprotein-cholesterol.

### What Are the Clinical Implications?

- This rapid conversion of the Kupffer cell subset by LPS, consequent loss of CETP expression and subsequent increase in plasma high-density lipoproteins may play a role in the host defense against Gram-negative bacterial infections.
- The strong association between the expression of CETP and activation markers by Kupffer cells implies that modulating high-density lipoprotein metabolism via CETP inhibition may affect the inflammatory status of the liver.

receptor 4 (TLR4) signaling pathway to release proinflammatory cytokines, such as tumor necrosis factor  $\alpha$  (TNF $\alpha$ )<sup>6</sup> and interleukin-1 $\beta$  (IL-1 $\beta$ ).<sup>7</sup> Therefore, KCs are crucial to detect LPS and trigger an antibacterial response.<sup>8,9</sup>

We have recently shown that KCs are the main source of plasma cholesteryl ester transfer protein (CETP), and that plasma CETP concentration predicts hepatic macrophage content in humans.<sup>10</sup> In that study, we also found that CETP was expressed by only a subset of hepatic macrophages in livers of both humans and mice transgenic for human CETP. Plasma CETP plays a pivotal role in the metabolism of high-density lipoproteins (HDL) and (very-) low-density lipoproteins (VLDL) by mediating the exchange of cholesteryl ester for triglycerides (TG) between HDL and (V)LDL. Genetic deficiency for CETP increases plasma HDL-cholesterol (C) and decreases cardiovascular events.<sup>11</sup> This has led to the development of CETP inhibition as a potential strategy for the treatment of cardiovascular disease. Despite clearly favorable effects on the lipoprotein profile, pharmacological CETP inhibitors, such as torcetrapib,<sup>12</sup> dalcetrapib<sup>13</sup> and evacetrapib,<sup>14</sup> failed to show clinical benefit on cardiovascular disease outcomes including atherosclerosis and vascular inflammation. While, recently, the Merck Company announced that the REVEAL (Evaluation of the Effects of Anacetrapib through Lipid Modification) study, which studies the effects of Anacetrapib on cardiovascular disease outcome met its primary end point, significantly reducing major coronary events defined as the composite of coronary death, myocardial infarction, and

coronary revascularization.<sup>15</sup> These results illustrate that the role and underlying mechanism of CETP in cardiovascular disease pathology is more complex than initially anticipated.

CETP not only has a role in lipid and lipoprotein metabolism, but also belongs to the family of lipid transfer/LPS-binding proteins (LT/LBP).<sup>16</sup> A previous study has demonstrated that CETP expression increases the mouse survival rate after injection of a lethal dose of LPS.<sup>17</sup> In addition, LPS administration to CETP transgenic mice resulted in a rapid and marked decrease in plasma CETP concentration and hepatic CETP expression, accompanied by an increase in HDL-C level.<sup>18</sup> These data indicate that CETP may play a complex role in the response to LPS.

We previously observed that a subset of F4/80-positive hepatic macrophages co-express CETP.<sup>10</sup> In the current study, we determined which subset of KCs is the predominant cellular source to the plasma CETP pool. Also, we investigated the role of KC subsets in the mechanism by which LPS reduces CETP expression. To this end, we determined the regulation of CETP in relation to hepatic macrophage markers after injection of LPS in APOE\*3-Leiden.CETP (E3L.CETP) mice and followed the kinetics of reappearance of CETP in relation to macrophage markers after removal of hepatic macrophages by liposomal clodronate. Furthermore, liver biopsies and plasma samples from 2 clinical studies were used to evaluate the CETP expression in KC subsets and effects of LPS on plasma CETP in humans.

## Methods

The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.

## Animals and Experimental Procedure

Female APOE\*3-Leiden.CETP (E3L.CETP) transgenic mice<sup>19</sup> were housed under standard conditions with a 12-hour light-dark cycle and had free access to food and water during the experiment. At the age of 10 to 15 weeks, mice were fed a semi-synthetic cholesterol-rich diet, containing 15% (w/w) cacao butter, 1% (w/w) corn oil and 0.1% cholesterol (w/w, Western-type diet; AB-Diets, Woerden, The Netherlands) for a run-in period of 6 weeks, followed by LPS injection or liposomal clodronate injection. Body weight and food intake were monitored during this study. The Institutional Ethics Committee for Animal Procedures from the Leiden University Medical Centre, Leiden, The Netherlands, approved the following studies.

## LPS Injection

After randomization according to plasma levels of triglycerides, total cholesterol, HDL-C, body weight, and age, mice

received an intraperitoneal injection of LPS (25- $\mu$ g per mouse; *Escherichia coli* serotype 055:B5, Sigma-Aldrich) or vehicle (LPS-free phosphate-buffered saline, control group), and blood samples were drawn before and 8, 24, and 48 hours after the injection. In a second study, mice were terminated 4, 8, and 48 hours after the injection of LPS.

### Liposomal Clodronate Injection

After randomization according to plasma total cholesterol (TC), HDL-C, triglycerides, body weight and age, ensuring that all mice were equally old when they were euthanized, mice received 2 intraperitoneal injections of liposomal clodronate (20 mg/kg bodyweight; purchased from Dr N. van Rooijen, Amsterdam) at a 3-day interval to deplete macrophages from the liver.<sup>10</sup> Blood samples were drawn before and after the second injection weekly up to 9 weeks. In a second study, mice were terminated 3 days (0 week), or 3, 6, or 9 weeks after the second injection. Control mice received no liposomal clodronate treatment.

### Blood Sampling, Plasma Lipid, and Lipoprotein Profiles

Blood was obtained via tail vein bleeding into heparin-coated capillary tubes. The tubes were placed on ice and centrifuged, and obtained plasma was snap-frozen in liquid nitrogen and stored at  $-80^{\circ}\text{C}$  until further measurements. Plasma was assayed for triglycerides and cholesterol using the commercially available enzymatic kits 11488872 and 236691 (Roche Molecular Biochemicals, Indianapolis, IN, USA), respectively. To measure plasma HDL-C, apoB-containing lipoproteins were precipitated from plasma with 20% polyethylene glycol 6000 (Sigma Aldrich) in 200 mmol/L glycine buffer (pH 10) and HDL-C was measured in the supernatant. Plasma non-HDL-C was calculated by subtracting HDL-C from plasma total cholesterol.

### Plasma CETP Concentration

Plasma CETP concentration was measured using the DAIICHI CETP ELISA kit according to manufacturer's instructions (Daiichi, Tokyo, Japan).

### Hepatic Gene Expression

Liver pieces were isolated and total RNA was extracted using the Nucleospin RNAII kit (Macherey-Nagel) according to manufacturer's protocol. RNA concentration was determined by Nanodrop technology (Thermo Scientific). Total RNA was reverse-transcribed with the iScript cDNA synthesis kit (Bio-Rad) and qPCR was performed using a CFX96 (Bio-Rad). Gene expression was normalized to Beta-2 microglobulin ( $\beta 2m$ ), hypoxanthine ribosyltransferase (*Hprt*) and Beta-actin ( $\beta actin$ ).

Relative expression was calculated and normalized to control group using Bio-Rad CFX Manager™ software 3.0 (Bio-Rad). Primer sequences can be found in Table S1.

### Liver Histology

Paraffin-embedded sections of mouse liver (5  $\mu$ m) were stained for F4/80 and human CETP (ab51771; 1/1000, Abcam) as described previously,<sup>10</sup> Clec4f (MAB2784; 1/1000, R&D Systems), Vsig4 (AF4674; 1/1000, R&D Systems) and Ly6C (ab15627; 1/400, Abcam). For immunofluorescence staining, the secondary antibodies donkey anti-rabbit Alexa488 (A21206; Invitrogen) and goat anti-rat Alexa555 (A21434; Invitrogen) were used. Finally, tissue sections were mounted with VECTASHIELD® Mounting Medium with DAPI (Vector Laboratories). Positive cells were counted using a LeicaCTR5500 fluorescence microscope (Leica Microsystems GmbH). Representative pictures of immunostaining for CETP in liver sections of non-CETP transgenic mice (APOE\*3-Leiden mice), APOE\*3-Leiden.CETP transgenic mice, and a healthy human donor are shown in Figure S1.

### Design of Human Studies

Ninety-three severely obese subjects (BMI 30–74) underwent elective bariatric surgery from 2006 to 2009 at the Department of General Surgery, Maastricht University Medical Center, Maastricht, The Netherlands, as described.<sup>20</sup> Subjects using anti-inflammatory drugs or having acute or chronic inflammatory diseases, degenerative diseases, and subjects reporting alcoholic intake  $>10$  g/day, were excluded. During surgery, liver biopsies were taken for mRNA isolation and in situ analyses. Venous blood samples were obtained after overnight fasting ( $\approx 8$  hours) on the morning of surgery for analysis of the plasma CETP concentration. This study was approved by the Medical Ethics Board of Maastricht University Medical Centre, in line with the Declaration of Helsinki. All participants provided informed written consent.

The second study consisted of 20 healthy male subjects as described.<sup>21</sup> Subjects with known genetic causes for low HDL-cholesterol, secondary dyslipidemias such as familial combined hyperlipidemia, metabolic syndrome or secondary to hypertriglyceridemia, were excluded. On the morning of the study day at 7:30 AM after an overnight fast, study participants were admitted to the research unit. At 7:45 AM a catheter was inserted in an antecubital vein of each arm. At 8:00 AM (time [t]=0), blood was drawn for baseline measurements. Subsequently, subjects received a bolus infusion of 1 ng/kg body weight of endotoxin (*E coli* LPS, catalog number 1235503, lot G2B274; United States Pharmacopeial Convention Inc, Rockville, MD) in the antecubital vein of the contralateral arm. The next morning at 8:00 AM, 24 hours after endotoxin infusion, study participants

returned after an overnight fast for the blood withdrawal. The study protocol was approved by the institutional review board at the Academic Medical Center in Amsterdam. Written informed consent was obtained from all subjects.

### In Vitro LPS Simulation in Human Monocyte-Derived Macrophages

Peripheral blood mononuclear cells were isolated from a buffycoat (Sanquin blood supply, Amsterdam, the Netherlands) through density centrifugation using Lymphoprep™ (Axis-Shield, Dundee, Scotland). Monocytes were then purified using human CD14 magnetic beads and MACS® cell separation columns (Miltenyi Biotec, Bergisch Gladbach, Germany). Monocytes were plated in 24-well tissue culture plates at a density of  $1 \times 10^6$  cells/mL (500  $\mu$ L per well) and differentiated to macrophages for 6 days in Iscove's Modified Dulbecco's Medium (Sigma-Aldrich) supplemented with 2 mmol/L L-glutamine, penicillin (100 U/mL), streptomycin (100  $\mu$ g/mL) and 10% fetal calf serum (All Gibco, Waltham, MA) in the presence of 50 ng/mL macrophage colony stimulating factor (M-CSF) (Miltenyi Biotec, Bergisch Gladbach, Germany). On day 3, the medium was removed and substituted by fresh Iscove's Modified Dulbecco's Medium with 10% fetal calf serum and 50 ng/mL M-CSF. On day 6, all medium was removed and replaced by Iscove's Modified Dulbecco's Medium with 10% fetal calf serum without M-CSF and cells were activated for 18 hours with vehicle (DMSO), LPS (10 ng/mL, Sigma-Aldrich), a liver X receptor (LXR) agonist (TO-901317, 10  $\mu$ mol/L, Sigma-Aldrich), and LPS+LXR agonist. Total RNA was extracted from the cell lysate.

### Statistical Analysis

Data were analyzed by Graphpad Prism software, version 7, unless indicated otherwise. Significance of differences between the groups was calculated non-parametrically using a Mann-Whitney *U* test for independent samples. All groups were compared with the control group. Bonferroni's method was used to determine significance in case of multiple comparisons. For the human LPS exposure study, the Student paired *t* test was used. To analyze the in vitro LPS exposure study, One-way ANOVA was used, followed by the Fisher's Least Significant Difference (LSD) test to identify the differing groups. Spearman correlation was used to determine the correlations between parameters in both mouse and human studies. Linear regression analysis was performed on the associations between hepatic expression of CETP and macrophage markers and the coefficients of determination ( $R^2$ ) were reported. For linear regression analysis of human liver microarray data, unadjusted Crude models (model 1) and a Model adjusted for age and sex (model 2) were applied using

STATA Statistical Software, version 12.0. For experiments involving repeated measures of plasma lipids and CETP levels in the same animal, we used a linear mixed-effects model with a heterogeneous first-order autoregressive covariance matrix structure to model subject-specific deviances from the group mean using IBM SPSS Statistical Software, version 23. Values are presented as means $\pm$ SEM. *P* values <0.05 were considered statistically significant for single comparison.

## Results


### LPS Reduces Hepatic CETP Expression, Paralleled by Decreased Expression of Resting Kupffer Cell Markers and Increased Expression of Macrophage Activation Markers

To investigate the role of hepatic macrophages in the mechanism by which LPS reduces CETP expression, we determined the regulation of CETP in relation to macrophage markers after injection of LPS in E3L.CETP mice. As expected, LPS injection caused a massive upregulation of hepatic mRNA expression of *Tnfa* 2.1-fold, *Il-1 $\beta$*  19-fold, and *Mcp-1* (monocyte chemotactic protein-1) 28-fold at 4 hours after injection (all  $P < 0.001$ , Figure 1A), indicating LPS-induced KC activation.<sup>6,7,22</sup> LPS also increased the expression of lipopolysaccharide-binding protein (*Lbp*, Figure S2A). These effects were transient as gene expression returned to baseline at 48 hours after injection. LPS markedly decreased mRNA expression of *Pltp* (phospholipid transfer protein) (Figure S2B) and ATP binding cassette subfamily G member 1 (*Abcg1*) (Figure S2C) in liver, up to 48 hours after LPS injection. Simultaneously, LPS injection rapidly and markedly decreased hepatic mRNA expression of *CETP* (−75% at 8 hours after injection;  $P < 0.001$ , Figure 1B) in E3L.CETP mice. At 48 hours after LPS injection, *CETP* expression was still reduced. In parallel, LPS markedly decreased the hepatic expression of resting KC markers *Clec4f* and *Vsig4* to a similar extent (−75% and −83% at 8 hours after injection;  $P < 0.01$ , Figure 1B). In contrast, LPS increased hepatic mRNA expression of lymphocyte antigen 6 complex locus C (*Ly6C*), a marker of infiltrating monocytes/macrophages<sup>23</sup> (+48% at 8 hours after injection;  $P < 0.001$ , Figure 1D). Correlation analyses using data of all time points (Figure 1D) showed that hepatic *CETP* expression strongly positively correlated with the expression of *Clec4f* ( $r = 0.735$ ;  $P < 0.001$ ) and *Vsig4* ( $r = 0.904$ ;  $P < 0.001$ ), whereas hepatic expression of *CETP* inversely correlated with *Ly6C* ( $r = -0.493$ ;  $P < 0.05$ ).

### LPS Acutely Changes Kupffer Cell Subsets But Not the Hepatic F4/80<sup>+</sup> Cell Number

We next performed immunohistochemistry on liver sections and the numbers of F4/80<sup>+</sup>, Ly6C<sup>+</sup>, Clec4f<sup>+</sup> and CETP<sup>+</sup> cells





**Figure 1.** LPS reduces hepatic CETP expression, paralleled by decreased expression of resting Kupffer cell markers and increased expression of macrophage activation markers. Female APOE\*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with 25  $\mu$ g LPS, after which mice were euthanized at the indicated time points. Livers were assayed for mRNA of (A) *Tnfa*, *Il-1 $\beta$* , *Mcp-1*; (B) *CETP* and (C) *Clec4f*, *Vsig4*, *Ly6c*. The correlations between hepatic mRNA expression of *CETP* with *Clec4f*, *Vsig4* and *Ly6c* were performed, and the goodness of fit  $R^2$  from linear regression analyses were shown (D). For (A through C) data are presented as means  $\pm$  SEM (0, 4, and 48 hours group: n=7; 8 hours group: n=8); \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 as compared with the 0-hour group. CETP indicates cholesteryl ester transfer protein; *Clec4f*, C-type lectin domain family 4; *Il-1 $\beta$* , interleukin-1 $\beta$ ; LPS, lipopolysaccharide; *Ly6c*, lymphocyte antigen 6 complex locus C; *Mcp-1*, monocyte chemoattractant protein-1; *Tnfa*, tumor necrosis factor  $\alpha$ ; *Vsig4*, V-set and immunoglobulin domain containing 4.

were quantified. LPS administration did not affect the hepatic total macrophage/monocyte content as evidenced by the number of F4/80<sup>+</sup> cells (Figure S3A). In line with the observation that LPS markedly increased the gene expression of *Ly6c*, LPS significantly increased the number of Ly6C<sup>+</sup> monocytes after 4 hours (2.6-fold) and 8 hours (3.4-fold) (Figure S3B). LPS decreased the number of Clec4f<sup>+</sup> KC only after 48 hours (–28%;  $P$ <0.01, Figure S3C), which coincided with a tendency of a decreased number of CETP<sup>+</sup> cells at 48 hours after injection (–20%;  $P$ =0.06, Figure S3D). The numbers of Clec4f<sup>+</sup> cells and CETP<sup>+</sup> cells were not affected at 4 and 8 hours after LPS injection, which may be explained by a relatively slow turnover of CETP protein as compared with mRNA. Collectively, these data indicate that LPS acutely decreases hepatic CETP expression accompanied by changes in KC subsets.

### LPS Reduces Plasma CETP and Transiently Increases Plasma HDL-C Level and HDL-C/Non-HDL-C Ratio

Plasma CETP, lipid and lipoprotein concentrations were assayed at baseline and 8, 24, 48 hours after LPS or vehicle injection in E3L.CETP mice. LPS rapidly reduced plasma CETP concentration already at 8 hours as compared with the control group (–51%;  $P$ <0.01, Figure 2A), and this reduction in plasma CETP concentration persisted until 48 hours after injection, consistent with the reduced hepatic *CETP* mRNA expression. As compared with the control group, LPS significantly decreased plasma TG level after 24 and 48 hours (Figure 2B), and total cholesterol level throughout the 48 hours (Figure 2C). To investigate the effect of LPS on the distribution of cholesterol over plasma lipoproteins, HDL-C and non-HDL-C levels were


determined. LPS transiently tended to increase HDL-C level 8 hours after injection (+81%; Figure 2D), while persistently decreasing non-HDL-C level throughout the 48 hours (Figure 2E). As a result, the HDL-C/non-HDL-C ratio transiently increased at 8 hours after LPS injection (Figure 2F), suggesting that LPS induced a rapid and transient shift of cholesterol from non-HDL lipoproteins to HDL.

### Reappearance of Hepatic CETP Expression After Elimination of Hepatic Macrophages Coincides With Reappearance of Hepatic *Clec4f* and *Vsig4* Expression


Since LPS administration has similar time-dependent effects on *CETP* expression and expression of the KC markers *Clec4f* and *Vsig4*, we reasoned that *CETP*, *Clec4f* and *Vsig4* may be co-expressed by a similar subset of macrophages. This would imply that, following elimination of hepatic macrophages, reappearance of hepatic *CETP* expression caused by monocyte infiltration would coincide with reappearance of *Clec4f* and *Vsig4*. Therefore, in a next experiment we eliminated

hepatic macrophages from E3L.CETP mice by clodronate injection, without induction of inflammation,<sup>24,25</sup> and followed the reappearance of *CETP* and macrophage markers in the liver.

In line with our previous study,<sup>10</sup> liposomal clodronate rapidly and markedly decreased plasma *CETP* concentration compared with vehicle (−75%; Figure 3A). The plasma *CETP* concentration was only gradually restored to levels observed in the control group at 8 weeks after injection. Similarly, liposomal clodronate virtually depleted the liver from *CETP* mRNA (−92%), which slowly returned to baseline levels (control group) only 9 weeks after the injection. In contrast, liposomal clodronate induced an immediate decrease in *F4/80* mRNA (−82%), which was restored already 3 weeks after injection (Figure 3B). Notably, the immediate effect of liposomal clodronate treatment on mRNA expression of *Clec4f* and *Vsig4* paralleled the *CETP* mRNA expression, while liposomal clodronate had virtually no effect on *Ly6C* mRNA (Figure 3B). Furthermore, data on protein expression of the macrophage subset markers are in line with data on mRNA expression (Figures 3C and 4).



**Figure 2.** LPS reduces plasma CETP, and transiently increases plasma HDL-cholesterol level and HDL-C/non-HDL-C ratio. Female APOE\*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with 25  $\mu$ g LPS or vehicle (control), after which blood samples were collected at the indicated time points. Plasma was assayed for CETP concentration and data are expressed relative to t=0 (A). Plasma levels of triglyceride (B), total cholesterol (C), HDL-cholesterol (HDL-C, D), non-HDL-C (E) were determined, and the ratio between HDL-C and non-HDL-C (F) was calculated. Data are presented as means $\pm$ SEM (control and LPS group: n=7); \* $P$ <0.05, \*\* $P$ <0.01, \*\*\* $P$ <0.001 as compared with the control group. CETP indicates cholesteryl ester transfer protein; HDL-C, high-density lipoprotein-cholesterol; LPS, lipopolysaccharide.



**Figure 3.** Reappearance of hepatic CETP expression after removal of hepatic macrophages coincides with reappearance of hepatic Clec4f and Vsig4 but not Ly6C. Female APOE\*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with liposomal clodronate (Lip Clo) and euthanized 3 days (0), 3, 6, and 9 weeks after injection. Untreated mice were taken along as control. Blood samples were collected at the indicated time points and plasma was assayed for plasma CETP (A). Livers were assayed for mRNA (B) and protein (C) of CETP, F4/80, Clec4f, Vsig4 and Ly6C. Data are presented as means±SEM (control and 0-week group: n=9; 3, 6, and 9 weeks group: n=7). \* $P<0.05$ , \*\* $P<0.01$ , \*\*\* $P<0.001$  compared with the control group. CETP indicates cholesteryl ester transfer protein; Clec4f, C-type lectin domain family 4; Lip Clo, liposomal clodronate; Ly6C, lymphocyte antigen 6 complex locus C; Vsig4, V-set and immunoglobulin domain containing 4.

Correlation analyses between hepatic expression of *CETP* and macrophage marker genes (Figure 5A through 5C), or the number of *CETP*<sup>+</sup> cells and *Clec4f*<sup>+</sup> cells, *Vsig4*<sup>+</sup> cells, as well as *Ly6C*<sup>+</sup> cells (Figure 5D and 5E), again showed strong positive correlations between *CETP* and *Clec4f* (Figure 5A and 5D) or *Vsig4* (Figure 5B and 5E), and less clear correlation between *CETP* and *Ly6C* (Figure 5C and 5F).

### CETP is Exclusively Expressed by Clec4f<sup>+</sup> Kupffer Cells


To assess whether the strong correlations observed between hepatic *CETP* and *Clec4f*/*Vsig4* (both mRNA expression and number of positive cells) are because of co-expression, we next performed double immunofluorescence staining of *CETP* and F4/80, *Clec4f*, or *Ly6C* on liver sections. Hepatic *CETP* co-localized in cells that also express F4/80, albeit that only a subset of F4/80<sup>+</sup> cells (65.4±9.9%) were *CETP* positive

(Figure 6A), which is in agreement with our previous findings.<sup>10</sup> While *Ly6C*<sup>+</sup> cells did not stain for *CETP* protein (only 4.4±3.9% *Ly6C*<sup>+</sup> cells were *CETP* positive, Figure 6B), 94.9±8.7% *Clec4f*<sup>+</sup> cells stained positive for *CETP* protein (Figure 6C).

### In Humans, Plasma CETP Concentration Correlates With Hepatic VSIG4 Expression and is Reduced by LPS Injection

By using previously generated microarray gene expression data from liver biopsies of 93 subjects who underwent elective bariatric surgery,<sup>20</sup> we evaluated the correlation between hepatic expressions of *CETP* with markers for macrophage subsets in humans. In line with findings from E3L.CETP mice, hepatic expression of *CETP* in humans correlated with *VSIG4* ( $r=0.441$ ;  $P<0.001$ , Figure 7A), but not *CD14* (Figure 7B), a marker for human monocytes.<sup>26</sup>





**Figure 4.** Reappearance of hepatic CETP protein and hepatic macrophage subsets after liposomal clodronate injection. Female APOE\*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with liposomal clodronate (Lip Clo) and euthanized 3 days (0), 3, 6, and 9 weeks after injection. Untreated mice were taken along as control (Con). Representative pictures of immunohistochemistry staining of CETP, F4/80, Clec4f, Vsig4 and Ly6C in liver sections from each group are shown. CETP indicates cholesteryl ester transfer protein; Clec4f, C-type lectin domain family 4; Lip Clo, liposomal clodronate; Ly6C, lymphocyte antigen 6 complex locus C; Vsig4, V-set and immunoglobulin domain containing 4.

Importantly, hepatic *VSIG4* expression significantly correlated with plasma CETP concentration in these subjects ( $r=0.303$ ;  $P<0.05$ , Figure 7C). Adjustment for age and sex did not change these findings (not shown). Also, from a publicly available large data set of subjects undergoing bariatric surgery,<sup>27</sup> we previously observed a high correlation between hepatic expression of CETP and the general macrophage marker MARCO ( $r=0.62$ ,  $P=1.74 \times 10^{-71}$ ).<sup>10</sup> Using data from the same database, we now observed an even better correlation between the hepatic expression of *CETP* and *VSIG4* ( $r=0.67$ ,  $P=5.27 \times 10^{-86}$ ) (Figure S4), which suggests that, in humans, CETP is also expressed by KCs.


To evaluate whether LPS lowers plasma CETP levels in humans similarly as in E3L.CETP mice, we determined CETP levels in 20 healthy males just before and 24 hours after administration of LPS.<sup>21</sup> Indeed, we observed that LPS also

decreases plasma CETP concentration in humans ( $-10\%$ ;  $P<0.001$ , Figure 7D).

### LPS Stimulation Decreases the LXR-Mediated Upregulation of CETP and VSIG4

In search for the underlying mechanism why KCs show decreased CETP expression in response to LPS, we performed an in vitro experiment using human peripheral blood monocyte-derived macrophages. As expected, treatment with the liver X receptor (LXR) agonist TO-901317 strongly increased mRNA expression of the target genes *ABCG1* (15-fold, Figure 7E) and *CETP* (6-fold, Figure 7F). Interestingly, stimulation with LPS decreased the LXR-mediated upregulation of *ABCG1* (Figure 7E) and *CETP* (Figure 7F), while LPS alone had no effect. Notably, the LXR agonist also increased the






**Figure 5.** Hepatic CETP mRNA and positive cells strongly correlate with those of Clec4f and Vsig4, but not Ly6C. The correlations between hepatic CETP mRNA (A through C) or protein (D through F) with Clec4f (A and D), Vsig4 (B and E) and Ly6c (C and F) were performed, and the goodness of fit  $R^2$  from linear regression analyses was shown. CETP indicates cholesteryl ester transfer protein; Clec4f, C-type lectin domain family 4; Ly6C, lymphocyte antigen 6 complex locus C; Vsig4, V-set and immunoglobulin domain containing 4.

expression of *VSIG4* (+39%;  $P < 0.05$ ), which was similarly counteracted by LPS stimulation (Figure 7G). Collectively, these data suggest that LPS decreases the LXR-mediated upregulation of CETP and VSIG4 in KCs.

## Discussion

In the present study, we investigated the role of KC subsets in the mechanism by which LPS reduces hepatic CETP expression and plasma CETP concentration. Our data showed that LPS rapidly and markedly reduces hepatic expression of CETP in parallel with KC activation and reduced expression of resting KC markers, without affecting the hepatic macrophage content. The reduction in hepatic CETP expression caused a decrease in plasma CETP concentration, and consequently a shift of plasma cholesterol from non-HDL lipoproteins to HDL. We next confirmed that hepatic CETP is exclusively confined to the resting KC subset (ie,  $F4/80^+Ly6C^-Clec4f^+Vsig4^+$ ), while being absent from immature monocytes and/or activated KCs in the liver (ie,  $F4/80^+Ly6C^+Clec4f^-Vsig4^-$ ). Our data indicated that LPS regulates CETP expression and plasma lipoprotein composition via activating the resting KC subset.


We have previously demonstrated that the liver is the main source of plasma CETP, and that hepatic macrophages are responsible for the expression of CETP in humans and CETP transgenic (E3L.CETP) mice.<sup>10</sup> Furthermore, a recent study in which hepatectomized mice were repopulated with human primary hepatocytes showed that these liver-humanized mice did not express CETP in the liver and completely lacked CETP in serum,<sup>28</sup> confirming that human hepatocytes do not express CETP. In addition, we observed that not all hepatic macrophages produce CETP, as supported by the fact that in the liver only 57% of  $F4/80^+$  macrophages co-express CETP in E3L.CETP mice and 39% of  $CD68^+$  macrophages co-express CETP in humans.<sup>10</sup> In the current study, double immunofluorescence staining of liver sections of E3L.CETP mice demonstrated that the CETP protein is confined to  $F4/80^+Ly6C^-Clec4f^+$  hepatic macrophages, and absent from  $F4/80^+Ly6C^+Clec4f^-$  macrophages. Additionally, the kinetics of the restoration of plasma CETP concentration and hepatic macrophage subsets upon liposomal clodronate injection indicated that  $F4/80^+Ly6C^-Clec4f^+$  macrophages in the liver are the predominant cellular source of the plasma CETP pool. It should be noted that  $F4/80$  is a general marker for



**Figure 6.** CETP protein is not co-localized with Ly6C protein, but does co-localize with Clec4f protein. Livers of non-injected female APOE\*3-Leiden-CETP mice were assayed for co-localization of CETP and F4/80 (A), Ly6C (B) and Clec4f (C). Red; F4/80, Ly6C or Clec4f, Green; CETP, Blue; DAPI. Double headed arrows indicate co-localization, single-headed arrows indicate no co-localization. CETP indicates cholesteryl ester transfer protein; Clec4f, C-type lectin domain family 4; Ly6C, lymphocyte antigen 6 complex locus C.

monocytes and macrophages including, but not restricted to, KCs.<sup>3,29</sup> Clec4f, also known as Kupffer cell receptor, has been identified as an exclusive marker for the resting KC.<sup>3,30</sup> The

reappearance of the different macrophage subsets indicated that Clec4f<sup>+</sup> KCs take longer to reappear in the liver than F4/80<sup>+</sup> macrophages (9 weeks versus 3–6 weeks), confirming



**Figure 7.** LPS reduces plasma CETP concentration that correlates with hepatic VSIG4 expression in humans. Ninety-three liver biopsies were taken during bariatric surgery, and assayed for gene expression by microarray analysis. The correlation between the expression of *CETP* and *VSIG4* (A) and *CD14* (B), and plasma CETP concentration and *VSIG4* expression (C) were determined, and the goodness of fit  $R^2$  from linear regression analyses was shown. D, Twenty healthy males received a bolus infusion of 1 ng/kg body weight of LPS via the antecubital vein. After an overnight fast, blood samples were collected before (baseline) and 24 hours after LPS infusion, and plasma CETP concentration was determined.  $***P < 0.001$  as compared with the baseline. E through G, Human monocyte-derived macrophages were treated with vehicle (control group), LPS (LPS group), TO-901317 (LXR group) and LPS+TO-901317 (LPS+LXR group). The mRNA expression of *ABCG1*, *CETP* and *VSIG4* was normalized to the Control group. Data are presented as means  $\pm$  SEM ( $n=4$ ).  $*P < 0.05$ ,  $**P < 0.01$ ,  $***P < 0.001$ . *ABCG1* indicates ATP binding cassette subfamily G member 1; *CD14*, cluster of differentiation 14; *CETP*, cholesteryl ester transfer protein; LPS, lipopolysaccharide; *VSIG4*, V-set and immunoglobulin domain containing 4.

that  $F4/80^+Clec4f^+$  KCs are more mature KCs than  $F4/80^+Clec4f^-$  macrophages. In contrast to mice, in humans *CLEC4F* expression is not confined to liver macrophages, while *VSIG4* is exclusively expressed by resting mature KCs.<sup>2,31</sup> Here, we showed in mice that *Vsig4* mRNA and protein expression paralleled the reappearance of *Clec4f* and

*CETP* expression. Gene expression analysis using microarrays of 93 liver biopsies obtained from bariatric surgery revealed a strong correlation between hepatic *CETP* expression and *VSIG4* expression in humans. Also, plasma CETP concentration correlates with *VSIG4* expression in human livers. Therefore, we conclude that hepatic *CETP* expression in



humans is also confined to resting KCs, which is thus the predominant pool of plasma CETP.

We showed that a bolus injection of LPS into E3L.CETP mice rapidly reduces hepatic *CETP* expression, without affecting total hepatic macrophage content as shown by the number of F4/80<sup>+</sup> cells, indicating that LPS reduced CETP expression in hepatic macrophages per se. This finding is in concordance with previous in vitro data showing that LPS, and other inflammatory stimuli, such as TNF $\alpha$  and interferon  $\gamma$  reduced *CETP* mRNA expression in bone marrow-derived macrophages from CETP transgenic mice and in human monocyte-derived macrophages.<sup>32</sup> In fact, LPS strongly reduced *Clec4f* expression in KCs in vitro.<sup>33</sup> Also, we now showed that upon LPS administration, hepatic *CETP* expression markedly positively correlates with the *Clec4f* expression, while it inversely correlates with the expression of *Ly6C* and macrophage activation markers, ie, *Tnf $\alpha$* , *Il-1 $\beta$*  and *Mcp-1*. This acute-phase rise in *Lbp* expression is probably mediated by proinflammatory cytokines, such as interleukin-1,<sup>34</sup> which has been shown to protect against LPS induced systemic inflammation.<sup>35</sup> We further observed that in healthy subjects, LPS also rapidly decreases plasma CETP concentration. Given the fact that hepatic CETP expression is confined to F4/80<sup>+</sup>Ly6C<sup>-</sup>Clec4f<sup>+</sup>Vsig4<sup>+</sup> resting mature KCs, our data indicate that LPS rapidly activates resting KCs to become Clec4f<sup>-</sup> macrophages in mice, or VSIG4<sup>-</sup> macrophages in human livers, simultaneously reducing hepatic CETP expression and decreasing plasma CETP concentration. The proinflammatory signals derived from activated KCs, such as TNF $\alpha$ , IL-1 $\beta$ , and MCP-1, may drive a vicious cycle activating F4/80<sup>+</sup>Ly6C<sup>-</sup>V-SIG4<sup>+</sup> KCs to lose the expression of VSIG4. Indeed, a previous study<sup>2</sup> has demonstrated that VSIG4 expression is restricted to resting macrophages and that expression was completely lost in inflamed macrophages.

The CETP gene promoter contains LXR binding elements,<sup>36</sup> and LXR activation strongly increases CETP gene expression and plasma CETP levels.<sup>37</sup> In addition, LXR signaling plays a crucial role in driving the specialization of macrophage subsets.<sup>38</sup> In pursuit of the underlying mechanism why KCs show decreased CETP expression in response to LPS, we treated human blood monocyte-derived macrophages with an LXR agonist, LPS or both. Our data are consistent with a mechanism in which LPS reduces the LXR-induced expression of CETP in macrophages. Interestingly, we observed that LXR activation also increased the expression of *VSIG4*, which was counteracted by LPS stimulation. Since the promoter of *VSIG4* contains no classical LXR-responsive element,<sup>39</sup> the exact mechanism underlying this upregulation is currently unknown but may involve a distal or non-classical LXR-responsive element. Nevertheless, it is thus likely that downregulation of CETP and VSIG4 by LPS in the macrophage are parallel events. Notably, LPS administration to mice also largely

decreased the mRNA expression of the LXR-target gene *Abcg1* in liver. Since *Abcg1* mRNA expression levels in KCs is 70-fold higher than in parenchymal hepatocytes,<sup>40</sup> our in vivo data confirm that LPS stimulation decreases LXR activation in KCs.

CETP is a member of the LPS binding protein (LBP) family, which includes PLTP (phospholipid transfer protein), BPI (bactericidal permeability increasing protein) and LBP itself. While LPS decreased *CETP* expression, it increased *Lbp* expression. Interestingly, the reduction in *Pltp* mRNA expression, which is in line with previous findings,<sup>41</sup> coincided with the reduction in *CETP* mRNA expression. CETP has a low binding affinity to LPS (Kd >25 nmol/L), as compared with LBP (Kd=0.8 nmol/L) and BPI (Kd=0.5 nmol/L).<sup>42</sup> Therefore, CETP likely only plays a role in LPS binding in the acute phase of LPS exposure, when circulating LPS concentration is high. This may explain the observation that CETP expression markedly improves the mouse survival rate after injection of a lethal dose of LPS.<sup>17</sup> In addition, CETP plays an important role in lipoprotein metabolism in humans. After secretion into the circulation, the CETP protein binds mainly to HDL, and promotes bidirectional transfer of CE, TG, and to lesser extent phospholipid between plasma lipoproteins. Upon LPS administration, reduced plasma CETP concentration results in increased HDL, which has well-documented anti-inflammatory properties.<sup>43,44</sup> A recent study showed that increasing HDL via CETP inhibition inhibited neointimal hyperplasia in balloon-injured rabbits, that the benefit was attributed to the anti-inflammatory properties of HDL.<sup>45</sup> In fact, it has previously been demonstrated that low HDL-C in healthy subjects was associated with an increased inflammatory response to an LPS challenge,<sup>21</sup> further supporting the anti-inflammatory role of endogenous HDL. It is thus tempting to speculate that CETP-expressing species have increased flexibility to respond to invading Gram-negative organisms that release endotoxin/LPS. The rapid conversion of KC subsets to lose CETP expression and subsequently increase HDL may be of importance in the defense against Gram-negative bacterial infections.

It should be mentioned that the E3L.CETP mice express the human CETP mini-gene under the control of its natural flanking regions.<sup>36</sup> Although it cannot be excluded that some regulatory elements may be missing from this construct, this human CETP transgenic mice were shown to respond in a human-like fashion to LXR agonism<sup>37</sup> and FXR agonism.<sup>46</sup> Notably, in E3L.CETP mice, the markedly increased HDL-C/non-HDL-C ratio was already normalized at 48 hours after LPS injection, whereas plasma CETP level and hepatic CETP mRNA expression were still lower at this time point. Moreover, in healthy subjects, 24 hours after LPS injection, they had decreased plasma TG<sup>21</sup> and CETP concentration as shown in the present study, while plasma HDL-C was not

changed.<sup>21</sup> Together, this indicates that LPS exposure not only affects CETP expression but also other pathways involved in lipoprotein metabolism.<sup>47</sup>

In conclusion, our findings show that hepatic CETP is exclusively expressed by resting KCs (ie, F4/80<sup>+</sup>Ly6C<sup>−</sup>Clec4f<sup>+</sup>) but not by activated macrophages or monocytes in the liver. In response to inflammatory stimuli, ie, LPS exposure, resting KCs become activated and lose CETP expression. As a consequence, plasma CETP concentration is also rapidly decreased and HDL-C is raised. This sequence of events may play a role in the host defense via the anti-inflammatory effects of HDL. The strong association between the expression of CETP and activation markers by KCs implies that modulating HDL metabolism via CETP inhibition may affect the inflammatory status of the liver.

## Sources of Funding

This study was supported by the framework of the Center for Translational Molecular Medicine (www.ctmm.nl), project PREDICt (grant 01C-104) to Willems van Dijk, the EU grant FP7-HEALTH-305707 to Groen: “A systems biology approach to RESOLVE the molecular pathology of 2 hallmarks of patients with metabolic syndrome and its co-morbidities; hypertriglyceridemia and low HDL-cholesterol”, the Centre for Medical Systems Biology (CMSB) and Netherlands Consortium for Systems Biology (NCSB), both within the framework of the Netherlands Genomics Initiative (NGI)/Netherlands Organisation for Scientific Research (NWO), “the Netherlands CardioVascular Research Initiative: the Dutch Heart Foundation, Dutch Federation of University Medical Centres, the Netherlands Organisation for Health Research and Development and the Royal Netherlands Academy of Sciences” for the GENIUS project “Generating the best evidence-based pharmaceutical targets for atherosclerosis” (CVON2011-19). PCN Rensen is an Established Investigator of the Dutch Heart Foundation (2009T038). Wang is supported by a VENI grant from NWO-ZonMW (91617027). Fu is supported by a NWO-VIDI grant (864.13.013) and CardioVasculair Onderzoek Nederland (CVON 2012-03).

## Disclosures

None.

## References

- Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren CM. CRlg: a macrophage complement receptor required for phagocytosis of circulating pathogens. *Cell*. 2006;124:915–927.
- Vogt L, Schmitz N, Kurrer MO, Bauer M, Hinton HI, Behnke S, Gatto D, Sebbel P, Beerli RR, Sonderegger I, Kopf M, Saudan P, Bachmann MF, VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. *J Clin Invest*. 2006;116:2817–2826.
- Yang CY, Chen JB, Tsai TF, Tsai YC, Tsai CY, Liang PH, Hsu TL, Wu CY, Netea MG, Wong CH, Hsieh SL. CLEC4F is an inducible C-type lectin in F4/80-positive cells and is involved in alpha-galactosylceramide presentation in liver. *PLoS One*. 2013;8:e65070.
- Lavin Y, Winter D, Blecher-Gonen R, David E, Keren-Shaul H, Merad M, Jung S, Amit I. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment. *Cell*. 2014;159:1312–1326.
- Harris RL, Musher DM, Bloom K, Gathe J, Rice L, Sugarman B, Williams TW Jr, Young EJ. Manifestations of sepsis. *Arch Intern Med*. 1987;147:1895–1906.
- Lichtman SN, Wang J, Lemasters JJ. Lipopolysaccharide-stimulated TNF-alpha release from cultured rat Kupffer cells: sequence of intracellular signaling pathways. *J Leukoc Biol*. 1998;64:368–372.
- Chensue SW, Terebuh PD, Remick DG, Scales WE, Kunkel SL. In vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. *Am J Pathol*. 1991;138:395–402.
- McCuskey RS, McCuskey PA, Urbaschek R, Urbaschek B. Kupffer cell function in host defense. *Rev Infect Dis*. 1987;9(suppl 5):S616–S619.
- Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. *Liver Int*. 2006;26:1175–1186.
- Wang Y, van der Tuin S, Tjeerdema N, van Dam AD, Rensen SS, Hendriks T, Berbee JF, Atanasovska B, Fu J, Hoekstra M, Bekkering S, Riksen NP, Buurman WA, Greve JW, Hofker MH, Shiri-Sverdlov R, Meijer OC, Smit JW, Havekes LM, van Dijk KW, Rensen PC. Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells. *Hepatology*. 2015;62:1710–1722.
- Thompson A, Di AE, Sarwar N, Erqou S, Saleheen D, Dullaart RP, Keavney B, Ye Z, Danesh J. Association of cholesteryl ester transfer protein genotypes with CETP mass and activity, lipid levels, and coronary risk. *JAMA*. 2008;299:2777–2788.
- Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med*. 2007;357:2109–2122.
- Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med*. 2012;367:2089–2099.
- Eyvazian VA, Frishman WH. Evacetrapib: another CETP inhibitor for dyslipidemia with no clinical benefit. *Cardiol Rev*. 2017;25:43–52.
- Kenilworth NJ. BUSINESS WIRE website. Available at: <http://www.busineswire.com/news/home/20170627005544/en/Merck-Update-REVEAL-Outcomes-Study-Anacetrapib>. Accessed June 27, 2017.
- Bingle CD, Craven CJ. Meet the relatives: a family of BPI- and LBP-related proteins. *Trends Immunol*. 2004;25:53–55.
- Cazita PM, Barbeiro DF, Moretti AI, Quintao EC, Soriano FG. Human cholesteryl ester transfer protein expression enhances the mouse survival rate in an experimental systemic inflammation model: a novel role for CETP. *Shock*. 2008;30:590–595.
- Masucci-Magoulas L, Moulin P, Jiang XC, Richardson H, Walsh A, Breslow JL, Tall A. Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. *J Clin Invest*. 1995;95:1587–1594.
- Westerterp M, van der Hoogt CC, de Haan W, Offerman EH, Dallinga-Thie GM, Jukema JW, Havekes LM, Rensen PC. Cholesteryl ester transfer protein decreases high-density lipoprotein and severely aggravates atherosclerosis in APOE\*3-Leiden mice. *Arterioscler Thromb Vasc Biol*. 2006;26:2552–2559.
- Wolfs MG, Rensen SS, Bruin-Van Dijk EJ, Verdarm FJ, Greve JW, Sanjabi B, Bruinenberg M, Wijmenga C, van Haeften TW, Buurman WA, Franke L, Hofker MH. Co-expressed immune and metabolic genes in visceral and subcutaneous adipose tissue from severely obese individuals are associated with plasma HDL and glucose levels: a microarray study. *BMC Med Genomics*. 2010;5:3–34.
- Birjmooh RS, van Leuven SI, Levels JH, van't Veer C, Kuivenhoven JA, Meijers JC, Levi M, Kastelein JJ, van der Poll T, Stroes ES. High-density lipoprotein attenuates inflammation and coagulation response on endotoxin challenge in humans. *Arterioscler Thromb Vasc Biol*. 2007;27:1153–1158.
- Mandrekar P, Ambade A, Lim A, Szabo G, Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. *Hepatology*. 2011;54:2185–2197.
- Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol*. 2011;11:723–737.
- Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury,

- inflammation, fibrosis, and carcinogenesis. *Proc Natl Acad Sci USA*. 2010;107:844–849.
25. van Rooijen N, Sanders A. Elimination, blocking, and activation of macrophages: three of a kind? *J Leukoc Biol*. 1997;62:702–709.
  26. Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. *Biomark Res*. 2014;2:1.
  27. Greenawalt DM, Dobrin R, Chudin E, Hatoum IJ, Suver C, Beaulaurier J, Zhang B, Castro V, Zhu J, Sieberts SK, Wang S, Molony C, Heymsfield SB, Kemp DM, Reitman ML, Lum PY, Schadt EE, Kaplan LM. A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. *Genome Res*. 2011;21:1008–1016.
  28. Minniti ME, Vedin LL, Wilson EM, Steffensen KR, Parini P. Liver-humanized mice exhibit lipoprotein-specific phenotypes when grafted with human hepatocytes from different donors. *Atherosclerosis*. 2017;263:e7.
  29. Klein I, Cornejo JC, Polakos NK, John B, Wuensch SA, Topham DJ, Pierce RH, Crispe IN. Kupffer cell heterogeneity: functional properties of bone marrow derived and sessile hepatic macrophages. *Blood*. 2007;110:4077–4085.
  30. Haltiwanger RS, Lehrman MA, Eckhardt AE, Hill RL. The distribution and localization of the fucose-binding lectin in rat tissues and the identification of a high affinity form of the mannose/N-acetylglucosamine-binding lectin in rat liver. *J Biol Chem*. 1986;261:7433–7439.
  31. Jung K, Kang M, Park C, Hyun CY, Jeon Y, Park SH, Seo SK, Jin D, Choi I. Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and natural killer T-cells. *Hepatology*. 2012;56:1838–1848.
  32. Lakomy D, Rebe C, Sberna AL, Masson D, Gautier T, Chevriaux A, Raveneau M, Ogier N, Nguyen AT, Gamber P, Grober J, Bonnotte B, Solary E, Lagrost L. Liver X receptor-mediated induction of cholesteryl ester transfer protein expression is selectively impaired in inflammatory macrophages. *Arterioscler Thromb Vasc Biol*. 2009;29:1923–1929.
  33. Beattie L, Sawtell A, Mann J, Frame TC, Teal B, de Labastida RF, Brown N, Walwyn-Brown K, Moore JW, MacDonald S, Lim EK, Dalton JE, Engwerda CR, MacDonald KP, Kaye PM. Bone marrow-derived and resident liver macrophages display unique transcriptomic signatures but similar biological functions. *J Hepatol*. 2016;65:758–768.
  34. Kirschning C, Unbehauen A, Lamping N, Pfeil D, Herrmann F, Schumann RR. Control of transcriptional activation of the lipopolysaccharide binding protein (LBP) gene by proinflammatory cytokines. *Cytokines Cell Mol Ther*. 1997;3:59–62.
  35. Lamping N, Dettmer R, Schröder NW, Pfeil D, Hallatschek W, Burger R, Schumann RR. LPS-binding protein protects mice from septic shock caused by LPS or gram-negative bacteria. *J Clin Invest*. 1998;101:2065–2071.
  36. Agellon LB, Walsh A, Hayek T, Moulin P, Jiang XC, Shelanski SA, Breslow JL, Tall AR. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. *J Biol Chem*. 1991;266:10796–10801.
  37. Luo Y, Tall AR. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. *J Clin Invest*. 2000;105:513–520.
  38. A-Gonzalez N, Guillen JA, Gallardo G, Diaz M, de la Rosa JV, Hernandez IH, Casanova-Acebes M, Lopez F, Tabraue C, Beceiro S, Hong C, Lara PC, Andujar M, Arai S, Miyazaki T, Li S, Corbi AL, Tontonoz P, Hidalgo A, Castrillo A. The nuclear receptor LXR $\alpha$  controls the functional specialization of splenic macrophages. *Nat Immunol*. 2013;14:831–839.
  39. Boergesen M, Pedersen TA, Gross B, van Heeringen SJ, Hagenbeek D, Bindesbøll C, Caron S, Lalloyer F, Steffensen KR, Nebb H, Gustafsson JA, Stunnenberg HG, Staels B, Mandrup S. Genome-wide profiling of liver X receptor, retinoid X receptor, and peroxisome proliferator-activated receptor  $\alpha$  in mouse liver reveals extensive sharing of binding sites. *Mol Cell Biol*. 2012;32:852–867.
  40. Hoekstra M, Kruijt JK, Van Eck M, Van Berkel TJ. Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells. *J Biol Chem*. 2003;278:25448–25453.
  41. Jiang XC, Bruce C. Regulation of murine plasma phospholipid transfer protein activity and mRNA levels by lipopolysaccharide and high cholesterol diet. *J Biol Chem*. 1995;270:17133–17138.
  42. Clark RW, Cunningham D, Cong Y, Subashi TA, Tkalecic GT, Lloyd DB, Boyd JG, Chrnyk BA, Karam GA, Qiu X, Wang IK, Francone OL. Assessment of cholesteryl ester transfer protein inhibitors for interaction with proteins involved in the immune response to infection. *J Lipid Res*. 2010;51:967–974.
  43. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM. Antiinflammatory properties of HDL. *Circ Res*. 2004;95:764–772.
  44. Morin EE, Guo L, Schwendeman A, Li XA. HDL in sepsis—risk factor and therapeutic approach. *Front Pharmacol*. 2015;6:244.
  45. Wu BJ, Li Y, Ong KL, Sun Y, Shrestha S, Hou L, Johns D, Barter PJ, Rye KA. Reduction of in-stent restenosis by cholesteryl ester transfer protein inhibition. *Arterioscler Thromb Vasc Biol*. 2017;37:2333–2341.
  46. Gautier T, de Haan W, Grober J, Ye D, Bahr MJ, Claudel T, Nijstad N, Van Berkel TJ, Havekes LM, Manns MP, Willems SM, Hogendoorn PC, Lagrost L, Kuipers F, Van Eck M, Rensen PC, Tietge UJ. Farnesoid X receptor activation increases cholesteryl ester transfer protein expression in humans and transgenic mice. *J Lipid Res*. 2013;54:2195–2205.
  47. König V, Hopf U, Moller B, Lobeck H, Assmann G, Freudenberg M, Galanos C. The significance of high-density lipoproteins (HDL) in the clearance of intravenously administered bacterial lipopolysaccharides (LPS) in mice. *Hepatogastroenterology*. 1988;35:111–115.




# **SUPPLEMENTAL MATERIAL**

**Table S1. Primers sequences use for RT-Qpcr.**

<b>Gene</b>	<b>Forward primer</b>	<b>Reverse primer</b>
<i>ABCG1</i>	CAGGAAGATTAGACACTGTGG	GAAAGGGGAATGGAGAGAAGA
<i>Abcg1</i>	AGGTCTCAGCCTTCTAAAGTTCCTC	TCTCTCGAAGTGAATGAAATTTATCG
<i>βactin</i>	AACCGTGAAAAGATGACCCAGAT	CACAGCCTGGATGGCTACGTA
<i>β-2m</i>	TGACCGGCTTGTATGCTATC	CAGTGTGAGCCAGGATATAG
<i>CETP</i>	CATGTCTCGGCTCGAGGTAG	TTCTGCTACAAGCCCCATCC
<i>Clec4f</i>	ACTGAAGTACCAAATGGACAATGTTAGT	GTCAGCATTACATCCTCCAGA
<i>F4/80</i>	CTTTGGCTATGGGCTTCCAGTC	GCAAGGAGGACAGAGTTTATCGTG
<i>Hprt</i>	TTGCTCGAGATGTCATGAAGGA	AGCAGGTCAGCAAAGAACTTATAG
<i>Il-1β</i>	GCAACTGTTCTGAACTCAACT	ATCTTTTGGGGTCCGTCAACT
<i>Lbp</i>	CCTGAGACTCGCCATCTCTGA	AGGAGGAGGTCCACTGAAATG
<i>Ly6c</i>	CTGCAACCTTGTCTGAGAGGA	GTCCCTGAGCTCTTTCTGCAC
<i>Mcp-1</i>	GCATCTGCCCTAAGGTCTTCA	TTCACTGTCACACTGGTCACTCCTA
<i>Pltp</i>	TCAGTCTGCGCTGGAGTCTCT	AAGGCATCACTCCGATTTGC
<i>Tnfa</i>	AGCCACGTCGTAGCAAACCAC	TCGGGGCAGCCTTGTCCCTT
<i>Vsig4</i>	TCACCTATGGCCACCCAC	AGGCGGCCTCTGTACTTTGCCT
<i>VSIG4</i>	CACTGACATGGATGGCTACCT	AAGACAGGCAGGCTCTTTCC


**Figure S1. CETP staining in mouse and human livers.**



Representative pictures of IHC staining of CETP protein in liver sections of (A) non-CETP transgenic mice (APOE\*3-Leiden mice), (B) APOE\*3-Leiden.CETP transgenic mice, and (C) a healthy human donor.




**Figure S2. LPS acutely increases hepatic *Lbp* expression and decreases *Pltp* and *Abcg1* expression.**




Female APOE\*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with 25  $\mu$ g LPS, after which mice were sacrificed at the indicated time points. Livers were assayed for mRNA of (A) *Lbp*, (B) *Pltp* and (C) *Abcg1*. Data are presented as means  $\pm$  SEM (n=7-8); \*\*P<0.01, \*\*\*P<0.001 as compared to the 0 h group.

Figure S3. LPS acutely changes hepatic macrophage subsets rather than macrophage number.



Female APOE\*3-Leiden.CETP mice fed a Western-type diet were intraperitoneally injected with 25  $\mu$ g LPS, after which mice were sacrificed at the indicated time points. Livers were assayed for F4/80-positive macrophages (A), Ly6C-positive monocytes (B), Clec4f-positive Kupffer cells (C) and CETP-positive cells (D). Data are presented as means  $\pm$  SEM (n=7-8); \*\*P<0.01, \*\*\*P<0.001 as compared to the 0 h group.

Figure S4. Hepatic *CETP* expression correlates with *VSIG4* expression in humans.



Scatter plots of the correlation between the expression of *CETP* and *VSIG4* in liver was determined by using a publicly available dataset consisting of 651 subjects<sup>1</sup>.



**Supplemental Reference:**

1. Greenawalt DM, Dobrin R, Chudin E, Hatoum IJ, Suver C, Beaulaurier J, Zhang B, Castro V, Zhu J, Sieberts SK, Wang S, Molony C, Heymsfield SB, Kemp DM, Reitman ML, Lum PY, Schadt EE, Kaplan LM. A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. *Genome Res.* 2011;21:1008-16.